Equities
Health CareHealth Care Equipment & Services
  • Price (USD)53.72
  • Today's Change-0.10 / -0.19%
  • Shares traded4.02m
  • 1 Year change20.50%
  • Beta0.8534
Data delayed at least 15 minutes, as of Jan 24 2020 21:00 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

  • Revenue in USD (TTM)3.37bn
  • Net income in USD-198.60m
  • Incorporated1990
  • Employees6.48k
  • Location
    Hologic Inc250 Campus DrMARLBOROUGH 01752-3020United StatesUSA
  • Phone+1 (508) 263-2900
  • Fax+1 (302) 655-5049
  • Websitehttps://www.hologic.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ABIOMED, Inc.820.28m220.82m8.26bn1.37k38.218.3534.7710.074.794.7917.8021.920.81561.839.74598,310.8021.9621.8624.3024.6482.8383.5726.9225.194.96--0.000.0029.5933.1893.92103.8973.97--
Masimo Corporation913.46m191.13m9.06bn1.50k49.888.1842.339.923.393.3716.1920.670.7582.997.89608,972.7015.8623.4218.0629.2466.8466.4020.9224.155.50--0.000.008.619.42-4.1227.2011.75--
Henry Schein, Inc.10.69bn491.38m10.45bn18.00k21.803.6815.300.97723.273.3171.0419.351.384.567.36594,003.606.387.7811.3513.6029.8427.714.624.590.921516.950.22540.005.946.67-7.533.378.52--
West Pharmaceutical Services Inc.1.79bn227.00m11.52bn7.70k51.677.7535.636.433.013.0523.7920.100.86985.525.79232,701.3010.688.7512.5810.3432.6932.2112.2810.032.3153.000.115922.767.404.65-12.1212.73-7.648.16
Insulet Corporation693.71m16.53m11.90bn1.17k757.4879.02299.8517.160.25420.254210.982.440.64393.208.81593,424.301.53-6.521.70-7.5365.8159.202.38-8.476.211.580.8675--21.5717.94112.41--85.93--
Steris PLC2.90bn335.96m12.83bn12.00k38.523.9722.634.433.933.9333.8838.080.56797.065.77241,507.806.614.447.184.8843.0041.0111.647.731.8611.190.268345.866.1911.3911.7818.6217.0410.16
DENTSPLY SIRONA Inc3.98bn160.70m13.27bn16.40k83.572.6227.493.340.71390.721517.7122.750.46422.975.68242,524.401.87-4.062.11-4.5252.2854.124.03-8.881.39162.960.2186---0.17786.2033.65--13.147.61
Varian Medical Systems, Inc.3.23bn298.10m13.48bn10.06k45.737.6134.444.183.243.1835.0919.470.8773.753.05320,522.808.118.5814.5015.0042.4942.579.2510.950.9787--0.18740.0010.481.12-16.66-5.88-8.34--
Hologic, Inc.3.37bn-198.60m14.19bn6.48k--6.8053.624.21-0.7447-0.76312.467.900.49263.905.48519,820.90-2.911.49-3.551.7851.9553.11-5.903.701.264.470.59250.004.645.8856.59--7.21--
Cooper Companies Inc2.65bn460.90m17.29bn12.00k38.114.7723.316.529.259.3653.2373.900.42841.846.55221,116.707.446.608.587.4466.2163.1117.3715.050.59117.520.33480.87774.769.0930.0111.304.180.00
Teleflex Incorporated2.56bn441.69m17.59bn15.20k40.496.1626.866.889.399.4354.3861.650.41042.486.63168,159.507.094.877.765.5557.0953.7917.2811.131.445.150.41226.2814.077.62-25.365.364.910.00
Align Technology, Inc.2.29bn418.91m21.28bn11.66k51.8616.3042.369.295.215.2128.4716.571.078.854.81196,486.2020.0317.8630.7124.1572.2475.0618.7019.731.62--0.000.0033.4724.3926.7744.1562.99--
Data as of Jan 24 2020. Currency figures normalised to Hologic Inc's reporting currency: US Dollar USD

Institutional shareholders

58.61%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 201942.17m15.73%
The Vanguard Group, Inc.as of 30 Sep 201929.86m11.13%
Parnassus Investmentsas of 30 Sep 201915.83m5.90%
BlackRock Fund Advisorsas of 30 Sep 201914.60m5.44%
Fidelity Management & Research Co. LLCas of 30 Sep 201912.72m4.74%
SSgA Funds Management, Inc.as of 30 Sep 201911.21m4.18%
Capital Research & Management Co. (World Investors)as of 30 Sep 201910.73m4.00%
Glenview Capital Management LLCas of 30 Sep 20198.21m3.06%
Wellington Management Co. LLPas of 30 Sep 20197.09m2.65%
Geode Capital Management LLCas of 30 Sep 20194.76m1.78%
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.